Molina Healthcare (MOH)
(Delayed Data from NYSE)
$325.43 USD
-4.87 (-1.47%)
Updated Oct 10, 2024 04:00 PM ET
After-Market: $325.43 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$325.43 USD
-4.87 (-1.47%)
Updated Oct 10, 2024 04:00 PM ET
After-Market: $325.43 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum D VGM
Zacks News
Should SPDR S&P MidCap 400 ETF (MDY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MDY
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Molina (MOH) to Join S&P 500 Driven by Medicare Performance
by Zacks Equity Research
Molina Healthcare (MOH) is likely to leave S&P MidCap 400 and replace IHS Markit Ltd. in the S&P 500 Index.
Integra's (IART) Q4 Earnings Top Estimates, Gross Margin Drops
by Zacks Equity Research
Integra (IART) records strong recovery in order demand in Q4 on broad-based strength in Neurosurgery and sales from the company's new CereLink ICP monitoring.
Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y
by Zacks Equity Research
Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong performance across all the geographic regions and segments.
Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Despite reporting a fourth-quarter loss, Glaukos' (GKOS) results reflect a noticeable rise in revenues.
Exact Sciences (EXAS) Q4 Revenues Top Estimates, Margin Down
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business saw strong momentum on solid Cologuard volume growth during the fourth quarter.
Tandem Diabetes (TNDM) Q4 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Robust domestic and international pump shipments are driving Tandem Diabetes' (TNDM) fourth-quarter top line.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Charles River (CRL) DSA Arm Sees Growth, Cell Supply Sluggish
by Zacks Equity Research
The acquisitions of Cognate BioServices and Vigene Biosciences contribute to the growth of Charles River's (CRL) Manufacturing Solutions arm.
Medtronic's (MDT) Q3 Earnings Beat, Revenues Lag Estimates
by Zacks Equity Research
Medtronic (MDT) registers organic growth in the Cardiovascular, Neuroscience and Diabetes segments in Q3.
Henry Schein (HSIC) Up 10.1% Since Posting Q4 Earnings Beat
by Zacks Equity Research
Henry Schein (HSIC) stock rallies on strong fourth-quarter performance and bullish 2022 EPS guidance.
Shockwave Medical (SWAV) Gains 3.2% Post Q4 Earnings Beat
by Zacks Equity Research
Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and expansion in gross margin.
UnitedHealth Group (UNH) Bolsters Presence With Contract Win
by Zacks Equity Research
UnitedHealth Group's (UNH) unit UnitedHealthcare receives a contract from the District of Columbia aimed at improving health outcomes of District Dual Choice program enrollees in the district.
AMN Healthcare (AMN) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q4 results demonstrate its segmental strength.
Syneos Health (SYNH) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Syneos Health (SYNH) reports better-than-expected earnings for the fourth quarter and strong performances by the Clinical Solutions and Commercial Solutions arms.
Globus Medical (GMED) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Strength in Musculoskeletal Solutions and Enabling Technologies products drove Globus Medical's (GMED) Q4 revenues.
Here's How Much You'd Have If You Invested $1000 in Molina a Decade Ago
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Baxter (BAX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results reflect robust performance across six of its business units.
West Pharmaceutical (WST) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter earnings reflect strength in the Proprietary Products segment and margin expansion.
Should Invesco S&P MidCap Quality ETF (XMHQ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for XMHQ
Charles River (CRL) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Robust demand for research models, particularly in China, as well as higher revenues from research model services aid Charles River (CRL) in Q4.
Alcon's (ALC) Q4 Earnings Top Estimates, Margins Increase
by Zacks Equity Research
According to Alcon (ALC), strong product flow results in above-market revenue growth, which drives core operating leverage and margin expansion.
Masimo's (MASI) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q4 sales.
PacBio's (PACB) Q4 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
PacBio (PACB) sees strength in Q4 segmental revenues, led by robust consumable and instrument sales.